Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Income - Net (2023 - 2025)

Historic Interest Income - Net for Guided Therapeutics (GTHP) over the last 3 years, with Q2 2025 value amounting to -$157000.0.

  • Guided Therapeutics' Interest Income - Net fell 10933.33% to -$157000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$546000.0, marking a year-over-year decrease of 10000.0%. This contributed to the annual value of -$378000.0 for FY2024, which is 3897.06% down from last year.
  • Guided Therapeutics' Interest Income - Net amounted to -$157000.0 in Q2 2025, which was down 10933.33% from -$147000.0 recorded in Q1 2025.
  • Guided Therapeutics' Interest Income - Net's 5-year high stood at -$61000.0 during Q1 2024, with a 5-year trough of -$157000.0 in Q2 2025.
  • For the 3-year period, Guided Therapeutics' Interest Income - Net averaged around -$95400.0, with its median value being -$73000.0 (2023).
  • Its Interest Income - Net has fluctuated over the past 5 years, first soared by 757.58% in 2024, then crashed by 14098.36% in 2025.
  • Over the past 3 years, Guided Therapeutics' Interest Income - Net (Quarter) stood at -$66000.0 in 2023, then crashed by 103.03% to -$134000.0 in 2024, then fell by 17.16% to -$157000.0 in 2025.
  • Its last three reported values are -$157000.0 in Q2 2025, -$147000.0 for Q1 2025, and -$134000.0 during Q4 2024.